Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) has reached full capacity at its current production site, fulfilling its expansion goals for early 2024. The company is advancing with plans for additional production facilities. This expansion, initiated after observing strong growth in new spider silk hybrids, will occur in two phases. The first phase, addressing near-term capacity needs, is set for completion within weeks. The larger second phase, which will provide hatchery space for the next 12-18 months, will conclude by early fall. Permitting has been approved, and construction is underway. CEO Kim Thompson emphasized the company's commitment to achieving ambitious spider silk production targets in 2024. The expansion aligns with Kraig Labs' vision for cost-effective, commercial-scale spider silk production. The third wave of recombinant spider silk production will begin this month, focusing on scaling up output.
Kraig Biocraft Laboratories announces a significant increase in spider silk production with the next generation of BAM-1 hybrid eggs. Following the successful production of the first BAM-1 hybrid cocoons, the company scaled up its egg production, marking the largest batch in its history. These eggs are scheduled for rearing within the next 30 days, aiming to optimize spider silk output over the next 60 days, despite August's challenging weather conditions. CEO Kim Thompson noted that the first half of 2024 has been the most productive period for the company, meeting aggressive goals for BAM-1 hybrids and expanding production capabilities.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the successful completion of cocoon production for its first commercial run of BAM-1 spider silk hybrids. The production, launched 30 days ahead of schedule, achieved a 10x increase in volume compared to spring trials, generating over 325 pounds of cocoons. This marks the largest batch of recombinant spider silk ever produced. Kraig Labs aims to scale up production further to meet its metric-ton-level goal, leveraging the robustness of BAM-1 hybrids for large-scale manufacturing. CEO Kim Thompson emphasized the success and potential for rapid scale-up in 2024.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a significant production update for its BAM-1 spider silk hybrid strain. The new batch, the largest in the company's history, is ten times the size of the spring trials and showcases record-breaking growth and robustness in silkworms.
The production batch is a major step forward in validating the rearing protocols and demonstrating the scalability of their spider silk production technology. CEO Kim Thompson emphasized that the mission of rapidly commercializing cost-effective and environmentally responsible spider silk production is progressing towards reality. The company plans to release cocooning and processing results over the coming weeks as it targets metric ton production levels.
Kraig Biocraft Laboratories (OTCQB: KBLB) announces the production of its BAM-1 recombinant spider silk hybrids, ahead of schedule due to successful production trials. This marks the company’s first true production-scale launch of these hybrids, representing over a 10x increase in production compared to spring trials. The BAM-1 hybrids, created by integrating Dragon Silk™ with robust silkworm strains, have shown excellent hatching yields, strong growth, and no signs of disease. This cycle aims to reach a production milestone of a metric ton of spider silk, with further updates promised in the coming weeks.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced significant advancements in the commercialization of its BAM-1 recombinant spider silk production hybrids, first introduced in February 2024. The BAM-1 platform has proven to be the most resilient and efficient system for large-scale spider silk production. This technology has successfully integrated the desirable properties of spider silk into production-ready silkworm strains, resulting in the advanced Dragon SilkTM. CEO Kim Thompson emphasized the scalability and reliability of the BAM-1 hybrids in accelerating the market transition of spider silk technologies. Following successful spring production trials, the company is ahead of its 2024 production schedule and plans to expand production further in the coming weeks.
Kraig Biocraft Laboratories (OTCQB: KBLB) has completed its spring spider silk production trials and is set to expand production in 2024. The company identified five key input parameters—nutrition, climate, genetic, staffing, and rearing conditions—that improved silkworm genetics and production processes, resulting in the largest and strongest silkworms and cocoons to date. Under the guidance of Dr. Nirmal Kumar, the team achieved significant advancements and is now accelerating the launch of larger-scale operations, starting nearly a month ahead of schedule with the next generation of BAM-1 spider silk hybrids.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced significant milestones, particularly the success of its spring production trials for spider silk. The company has heightened its investor communications and reviewed its investor relations (IR) program at the request of OTC Markets Group, ensuring all publications are compliant and factual. A recent editorial by 24/7 Market News highlighted advancements in spider silk, which the company verified as truthful. Kraig Labs has directed Hansel Capital and Karolus Maximus Kapital to provide shareholder updates, emphasizing a commitment to compliance and transparency. The company reported no insider trading or issuance of common stock in the past 90 days, except for the CEO acquiring one restricted share. Kraig Biocraft is focused on scaling production and maintaining high reporting standards.
Kraig Biocraft Laboratories, Inc. announces plans to expand production base into Cambodia to support the growth of its recombinant spider silk production. The Company's successful spring production trials have paved the way for rapid expansion and diversification of operations. With a target of one metric ton production before year's end, the Company aims to capitalize on its recent successes and continue scaling up its operations.
Kraig Biocraft Laboratories, Inc. (KBLB) announces successful spring production trials of its BAM-1 hybrid parental strains, exceeding expectations for scale, performance, and robustness. The trials demonstrated the readiness for rapid production expansion, marking the most successful cycle in the company's history. The parent strains showed strength and resilience, with no instances of disease. The company is now moving towards scaling production to metric ton levels.
FAQ
What is the current stock price of Kraig Biocraft Laboratories In (KBLB)?
What is the market cap of Kraig Biocraft Laboratories In (KBLB)?
